ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vaccination of GC3114B

A development code.

Its studies are mostly in Influenza, Human, led by GC Biopharma.

Furthest: phase 3, since Oct 11, 20261 company-led study, 1 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GC Biopharma11 open or runningphase 3since Oct 11, 2026Oct 11, 2026Mar 2028phase 3 · NCT07883928

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2026First study: phase 3 study in Influenza, HumanFirst studyNCT07883928 · 1,806 planned · South Korea

Ahead

  1. Mar 2028Primary completion: phase 3 study in Influenza, HumanNCT07883928

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07883928Influenza, Human · South Korea3RecruitingMar 20281,806

How it is read

Names in the registry

  • “vaccination of GC3114B”, 1 entry

Codes read as this program: GC3114B.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.